Form 4: RA Capital Management SEC Form 4 Filing for ACRV

RA Capital Management reports a restricted stock unit grant to director Derek DiRocco for Acrivon Therapeutics, Inc.

Summary

• RA Capital Management, L.P. filed a Form 4 regarding Acrivon Therapeutics, Inc. (ACRV).
• The filing details a grant of 9,366 restricted stock units (RSUs) to Dr. Derek DiRocco, a director of the issuer.
• The RSUs are scheduled to vest in full on March 18, 2027, contingent upon continuous service.
• Dr. DiRocco holds these RSUs for the benefit of RA Capital funds, with any resulting stock used to offset advisory fees.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting standard corporate governance and compensation practices.

Positives

• Alignment of director compensation with long-term equity incentives.
• Continued institutional support from a major shareholder (RA Capital Management).

Negatives

• None identified in this transaction filing.

Risks

• Vesting is subject to the director's continuous service through March 18, 2027.
• The reporting persons disclaim beneficial ownership of the RSUs, noting they are held for the benefit of the funds.

Future Outlook

The filing does not provide forward-looking financial guidance, focusing solely on the disclosure of equity compensation for a board member.

Management Comments

• The RSUs will vest in full on March 18, 2027, subject to Dr. DiRocco's continuous service as a director through such vesting date.
• Dr. DiRocco is obligated to turn over to the Adviser any stock received upon settlement of the RSUs, which will offset advisory fees.

Industry Context

StockSavvy.ai notes that this is a standard regulatory disclosure for institutional investors who have representatives serving on the boards of their portfolio companies in the biotechnology sector.

Comparison to Industry Standards

• The use of RSU grants for board compensation is standard practice for publicly traded biotech companies to align director interests with shareholders.
• The arrangement where a director's equity compensation is assigned to an investment firm to offset management fees is a common practice among venture capital and private equity firms.

Related Party Transactions

• Dr. Derek DiRocco serves as a director of the issuer and is a Partner of the Adviser (RA Capital Management, L.P.).

Stakeholder Impact

• Minimal impact on shareholders as this is a routine equity grant to a board member.

Next Steps

• Vesting of the RSU award on March 18, 2027.

Key Dates

Keywords

Acrivon Therapeutics, ACRV, RA Capital Management, Form 4, Insider Trading, Biotech, Equity Compensation